Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937950 · ClinicalTrials.gov registry record · Phase 3
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,022
- Enrollment target
NCT00937950: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00937950 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,022 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (162% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00937950, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,022 participants
- Enrollment target
Study Summary
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48). This follow-up study will also be offered to subjects who were pregnant at their last NCT00122681 study visit (Visit 10, Month 48) so that no cervical sample could be collected at that visit. The objectives \& outcome measures of the primary phase (study 008/580299) are presented in a separate protocol posting (NCT00122681).
Primary Outcome
Subjects who presented oncogenic HPV DNA in cervical samples by HPV DNA testing. The presence of oncogenic HPV infection was determined by the Hybrid Capture 2 (HCII) test, which detects HPV DNA types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Missing = For some of the subjects whose result was indicated as quantity not sufficient (QNS).
Interventions
- OTHER Gynaecological follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,022 participants |
| Start Date | 2009-08-05 |
| Est. Completion | 2014-01-20 |
| Phase | Phase 3 |
What the finished NCT00937950 record still lists
NCT00937950 is an interventional study that assigns participants to a tested intervention. Its 2,022 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (162% higher).
The record links to 0 conditions, and to 1 intervention - of which Gynaecological follow-up is the first listed.
NCT00937950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00937950 about?
NCT00937950 is a clinical study titled "Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects". This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48). ...
What is the current status of trial NCT00937950?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,022 participants. The study started on 2009-08-05. Estimated completion is 2014-01-20.
What interventions are being tested in trial NCT00937950?
The interventions under investigation include: Gynaecological follow-up (OTHER).
Who is sponsoring clinical trial NCT00937950?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00937950's enrollment target sits among peer trials
2,022 100th of 2000 higher than 1,901 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
- NCT05625659 · 2,032 participants · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI